Klotho Neurosciences, Inc. (KLTO) Stock
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.
Klotho Neurosciences, Inc. is headquartered in US.
Klotho Neurosciences, Inc. (KLTO) stock trades at $0.38 with a market capitalization of $20.08M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.13, reflecting a net loss over the last twelve months, price-to-book of 0.69, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.11 and $3.91, and currently trades 90.3% below its 52-week high.
On profitability, Klotho Neurosciences, Inc. generates a return on equity (ROE) of -108.82% (negative, reflecting a net loss), return on capital employed of -25.47%.
Official website: klothoneuro.com
Klotho Neurosciences, Inc. by the numbers, 2021–2025
Between 2021 and 2025 Klotho Neurosciences, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-11.0M.
On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-22.0M.
Borrowings stand at $0, cash on hand is $10.0M, cash from operations was $-6.0M in the latest year, positive in 0 of the last 5.
Return on equity has averaged -204.4% over five years, and was -122.2% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Klotho Neurosciences, Inc. (KLTO) — frequently asked questions
What is Klotho Neurosciences, Inc. (KLTO) stock price today?
Klotho Neurosciences, Inc. (KLTO) is currently trading at $0.38, down 7.1% today.
What is KLTO P/E ratio?
Klotho Neurosciences, Inc.'s P/E ratio is -1.13. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is KLTO return on equity (ROE)?
Klotho Neurosciences, Inc.'s return on equity (ROE) is -108.82%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Klotho Neurosciences, Inc.'s market cap?
Klotho Neurosciences, Inc. has a market capitalization of $20.08M.
Does KLTO pay a dividend?
Klotho Neurosciences, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does KLTO carry?
Klotho Neurosciences, Inc. has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is KLTO's profit margin?
Klotho Neurosciences, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is KLTO in?
Klotho Neurosciences, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is KLTO listed on?
Klotho Neurosciences, Inc. trades on NASDAQ under the ticker KLTO.
What is KLTO's 52-week range?
Over the last year Klotho Neurosciences, Inc. has traded between $0.11 and $3.91.
Related Healthcare Stocks
Popular Stocks
Screens KLTO currently matches
On the figures above, Klotho Neurosciences, Inc. passes the filters for 5 of our ready-made screens, among them Day Losers Stocks, Penny Stocks, Stocks Under $1. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.